차 인간 간세포의 분리 및 비 실질 간 세포의 주요 집단 대응을위한 프로토콜

Executive Industry Relevance

Access to purified primary human hepatocytes and non-parenchymal liver cells from a single donor enables the reconstruction of physiologically relevant human liver models for drug metabolism and toxicity testing. This capability supports mechanistic de-risking in early discovery by providing a disease-relevant system that maintains hepatocyte function through paracrine signaling from Kupffer cells, liver endothelial cells, and hepatic stellate cells. The method enhances predictive confidence in lead identification by reducing the biological variability associated with dedifferentiated monocultures.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses in a multicellular liver microenvironment that reflects in vivo patho-physiology.
• Operational Value: Provides a renewable source of phenotypically stable hepatocytes and NPCs for consistent target engagement assays.
• Scientific Value: Supports functional validation of targets involved in drug-induced liver injury through co-culture models that capture cell-cell communication.

Screening & Assay Development

• Scientific Value: Delivers qualified biological systems with defined cellular composition for assay standardization and reproducibility.
• Operational Value: Generates quantitative outputs such as albumin secretion, urea production, and CYP450 activity for reliable compound evaluation.
• Scientific Value: Facilitates phenotypic screening in 3D or co-culture formats that better predict clinical hepatotoxicity.

Translational & Preclinical Research

• Scientific Value: Offers a disease-relevant system for studying liver pathophysiology and evaluating therapeutic candidates in a human context.
• Operational Value: Enables translational biomarker discovery by correlating in vitro readouts with clinical outcomes.
• Scientific Value: Supports mechanistic de-risking by isolating the contribution of individual cell populations to liver injury pathways.

Pipeline & Workflow Integration

The isolated cell populations integrate into the discovery continuum from early target validation through lead identification to preclinical safety assessment, providing a continuous source of human liver biology for iterative model refinement.

• Discovery Biology: Supports hypothesis testing and pathway clarification by enabling functional readouts in co-cultures that mimic the liver sinusoid.
• Screening: Delivers assay-ready cells with high viability and standardized isolation for reproducible compound screening campaigns.
• Analytics: Provides quantitative dependent variable measurements such as metabolite formation, reactive oxygen species, and cytokine release for comparative condition analysis.
• Translational Research: Connects discovery findings to preclinical validation through a scalable source of primary human liver cells that maintain key functional markers.
• Enterprise Reuse: Establishes a reusable isolation platform that reduces dependency on variable tissue sources and supports cross-project consistency.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in hepatotoxicity assessment by maintaining hepatocyte differentiation and function through NPC co-culture.
• Operational Value: Ensures standardization and scalability of liver cell production from single donor samples, reducing batch-to-batch variability.
• Strategic Value: Improves go/no-go decisions by providing early, human-relevant safety data that reduces late-stage attrition due to liver toxicity.
• Portfolio Impact: Enables risk-adjusted prioritization of compounds based on mechanistic liver liability profiles derived from physiologically relevant models.

Implementation Considerations

• Requires expertise in perfusion techniques, density gradient centrifugation, and cell sorting procedures.
• Dependent on access to fresh human liver tissue and specialized equipment such as peristaltic pumps and magnetic cell separators.
• Necessitates cross-team standardization of isolation protocols to ensure consistent cell quality and viability across sites.
• Involves adaptation considerations when scaling from small tissue samples to larger-scale production for multi-well screening formats.
• Practical limitations include tissue donor variability and the time-sensitive nature of cell isolation post-resection, which must be managed through standardized SOPs.

Biopharma FAQs